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Abstract 
Purpose: A group of radiolabeled thymidine analogs were developed as radio-tracers for 
imaging herpes viral thymidine kinase (HSV1-tk) or its variants used as reporter gene. A 
transgenic mouse model was created to express tk upon liver injury or naturally occurring 
hepatocellular carcinoma (HCC). The purpose of this study was to use this unique animal 
model for initial testing with radio-labeled thymidine analogs, mainly a pair of newly emerging 
nucleoside analogs, D-FMAU and L-FMAU.  
Methods: A transgeneic mouse model was created by putting a fused reporter gene system, 
firefly luciferase (luc) and HSV1-tk, under the control of mouse alpha fetoprotein (Afp) 
promoter. Initial multimodal imaging, which was consisted of bioluminescent imaging (BLI) and 
planar gamma scintigraphy with [
125I]-FIAU, was used for examining the model creation in the 
new born and liver injury in the adult mice. Carcinogen diethylnitrosamine (DEN) was then 
administrated to induce HCC in these knock-in mice such that microPET imaging could be 
used to track the activity of Afp promoter during tumor development and progression by 
imaging tk expression first with [
18F]-FHBG. Dynamic PET scans with D-[
18F]-FMAU and 
L-[
18F]-FMAU were then performed to evaluate this pair of relatively new tracers. Cells were 
derived from these liver tumors for uptake assays using H-3 labeled version of PET tracers.  
Results: The mouse model with dual reporters: HSV1-tk and luc placed under the transcrip-
tional control of an endogenous Afp promoter was used for imaging studies. The expression 
of the Afp gene was highly specific in proliferative hepatocytes, in regenerative liver, and in 
developing fetal liver, and thus provided an excellent indicator for liver injury and cancer 
development in adult mice. Both D-FMAU and L-FMAU showed stable liver tumor uptake 
where the tk gene was expressed under the Afp promoter. The performance of this pair of 
tracers was slightly different in terms of signal-to-background ratio as well as tracer clearance. 
Conclusion: The newly created knock-in mouse model was used to demonstrate the use of 
the dual-reporter genes driven by well-characterized cancer-specific transcriptional units in 
conjunction with in vivo imaging as a paradigm in studying naturally occurring cancer in live 
animals. While BLI is suitable for small animal imaging with luc expression, PET with L-FMAU 
seemed be the choice for liver injury or liver cancer imaging with this animal model for future 
investigations. 
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Preclinical  testing  by  using  appropriate  tumor 
models in small animals represents an important step 
in the development of new therapeutic regimens as 
well  as  imaging  agents.  Recently,  genetically  engi-
neered  mouse  models  of  various  types  of  human 
cancers, including hepatocellular carcinoma (HCC) [1, 
2]  have  been  developed.  The  availability  of  these 
models has enabled the implementation of preclinical 
anti-tumor  drug  testing  in  a  natural  microenviron-
ment and thus provides a new and powerful para-
digm for drug development [3, 4]. Meanwhile, in vivo 
imaging enables  the evaluation of these therapeutic 
drugs in treating naturally occurring cancers in live 
animals.  To  combine  these  efforts,  a  mouse  model 
with imaging reporters to monitor HCC development 
and progression was created [5]. The alpha fetopro-
tein  (Afp)  is  a  secreted  polypeptide  whose  normal 
expression  is  strictly  restricted  to  developing  fetal 
tissues,  particularly  in  the  developing  fetal  liver  in 
both rodents and humans. It is also expressed in re-
generative liver injury and ultimately in liver tumor 
such as HCC. Approximately 70% of HCCs are posi-
tive for Afp, and levels of Afp increase with tumor 
progression [6]. A strategy was adopted to create a 
knock-in mouse model by putting the reporter genes, 
firefly luciferase (luc) and HSV1-tk, under the control 
of Afp promoter such that molecular imaging can be 
used to follow Afp promoter activity for liver damage, 
tumor  development  and  progression.  For  the  two 
genes knocked-in: tk is suitable for quantitative nu-
clear imaging by PET or scintigraphy, and luc for rel-
atively easy-use bioluminescent imaging (BLI) in high 
frequency screening/monitoring. 
There is a group of radiolabeled thymidine ana-
logs that have been tested for imaging herpes viral 
thymidine  kinase  (HSV1-tk)  or  its  variants  used  as 
reporter  gene  [7-9].  Initially,  radiolabeled 
2’-fluoro-2’-deoxy-1--D-arabinofuranosyl-5-iodourac
il (FIAU) was the tracer for imaging HSV1-tk expres-
sion  [10]  although  2'-[18F]fluoro-5-  ethyl-1-beta-D- 
arabinofuranosyluracil  (FEAU)  [11]  and  others  ap-
peared to be the tracers of choice for that purpose [12]. 
On the other hand, 9-[4-[18F]fluoro-3-(hydroxymethyl) 
butyl-]guanine (FHBG) was developed specifically for 
imaging a point-mutated version, the sr39tk [13]. In 
this study, FIAU was used during the initial phase of 
creating the knock-in mouse model. Once HCC was 
induced,  a  pair  of  thymidine  analogs, 
1-(2’-deoxy-2’-[18F]fluoro--D-arabinofuranosyl)thym
ine  (D-FMAU)  and  1-(2’-deoxy-2’-[18F]fluoro--L- 
arabinofuranosyl)thymine  (L-FMAU)  [14],  were 
compared  for  PET  imaging  of  tk  expression  in  this 
unique mouse model of induced HCC. FHBG, which 
incidentally showed uptake in some induced HCCs, 
was also tested. Chemical structure of these nucleo-
side analogs are shown in Figure 1. The use of this 
novel  mouse  model  with  the  matching  radiotracer 
instead of the conventional xenograft tumor models 
offered unique opportunity for studying liver injury, 
liver cancer development, and hopefully for evaluat-




Figure 1. Thymidine (TdR) and its analogs. Red-colored atoms are the positions for radiolabels: C for C-11/C-14, F for F-18, I for 




Materials and Methods 
Mouse model evaluation 
Knock-in  animal  model.  Gene  targeting  tech-
nology was used to create a mouse strain in which a 
tk-luc dual-reporter fusion gene cassette (designated 
as  Afp-tk-IRES-luc)  was  inserted  behind  the  Afp 
promoter  [5].  This  strategy  is  illustrated  in  Supple-
mentary Material: Figure S1. All mice generated were 
cared for in accordance with guidelines set forth by 
the American Association for Accreditation of Labor-
atory Animal Care and the USPHS "Policy on Human 
Care and Use of Laboratory Animals," and all studies 
were approved and supervised by Case Western Re-
serve  University  Institutional  Animal  Care  and Use 
Committee.  Our  prior  studies  have  shown  that  the 
expression profiles of tk and luc in these mice were 
identical to that of endogenous Afp gene. In addition, 
the  expression  of  these  exogenous  proteins  did  not 
result  in  any  significant  adverse  effects  to  these 
knock-in mice carrying the imaging alleles [5]. In this 
paper,  we  evaluated  these  mice  followed  by  HCC 
induction  with  carcinogen  with  both  BLI  and  mi-
croPET  with  different  radiolabeled  deoxynucleoside 
analogs. 
Initial  evaluations:  The  mouse  model  created 
using the above mentioned knock-in gene targeting 
approach  was  used  for  initial  evaluation  since  the 
expression of the endogenous Afp gene is highly spe-
cific for the developing fetal liver, and then liver in-
jury in adult mice. First, one day after birth, five (5) 
mouse  litters  that  weighed  1.4g  on  averaged  were 
weighed  precisely  for  calculating  the  amount  of 
D-luciferin (Biosynth AG, Switzerland) to be carefully 
injected i.p. into the individual pups at 75 g/kg body 
weight.  Then,  these  one-day-old  pups  were  placed 
confined to prevent movement during BLI, and posi-
tioned on the platform of a PIXIS 1000 cooled-CCD 
camera  system  (Princeton  Instrument,  Tucson,  AZ), 
which is one component of the dual-modality imaging 
system  built  by  Thomas  Jefferson  National  Lab 
(Newport  News,  VA).  3  minutes  after  injection  of 
D-luciferin,  6-minute-imaging  sessions  were  per-
formed. During imaging, the animal was not put un-
der any anesthesia. The litters were put back in the 
cage to let grow after the initial BLI. Signals from BLI 
in the liver indicated the expression of Afp. Three day 
after  birth,  pups  were  injected  with  15-20  µCi 
(0.555-0.74 MBq) of [125I]-FIAU. Two days after injec-
tion (5 days after birth), they were anesthetized and 
imaged  by  planar  scintigraphy  with  a  bronze  colli-
mator and X-ray at several time points on the same 
specially  designed  multimodality  imager  for  small 
animals until scintigraphic signals became clear after 
the washout of the non-binding FIAU. 
Liver injury: When the above mentioned trans-
genic mice grew into adults starting at week 8, CCl4 
(Sigma) was injected i.v. into four (4) of these animals. 
24 hrs later BLI imaging was performed for each an-
imal, in which  D-luciferin was injected i.p. into the 
mice at 100 g/kg body weight. 6 minutes after injec-
tion, the anesthetized animal was placed supine and 
tapped  at  the  plate  of  the  same  PIXIS  1000 
cooled-CCD camera for two 6 minutes imaging ses-
sions. During  imaging, the animal was under anes-
thesia with isoflurane gas (1.5% mixed with oxygen) 
through  a  gas  anesthesia  system  (EZAnesthesia, 
Palmer,  PA).  Before  imaging  the  front  of  the  mice 
were shaved to reduce the light absorption by the furs 
during BLI. Each animal was then injected with about 
80 Ci (2.96 MBq) of [125I]-FIAU in 200 L solution for 
imaging tk expression. The animal was then placed 
prone  on  the  second  imaging  platform  of  the  com-
bined tri-imaging modality system. This time, a pla-
nar X-ray image was taken followed by a 2 minutes 
planar gamma scintigraphic acquisition with the same 
bronze  collimator  specially  designed  for  imaging 
I-125 on small animal models. Throughout the imag-
ing  session,  the  gas  anesthesia  system  was  used  to 
keep the animal on the scanner. The 24 hr point after 
[125I]-FIAU injection (48 hrs post CCl4 treatment) was 
used as it was thought to be the optimal time point for 
imaging tk expression using labeleled FIAU [12]. 
HCC induction and model validate. Batches of 
transgenic mice and fewer wild type littermates were 
prepared for different imaging experiments described 
below. All were subjected to a single i.p. injection of 20 
µg/g body weight of diethylnitrosamine (DEN, Sig-
ma) 14 days after birth. By 9 months, these animals 
were subject to BLI and PET imaging for tumor de-
tection. After imaging, the animals were euthanized 
by overdosing with pentobarbital (~200 mg/kg) and 
cut open for photography and tissue harvesting. Liv-
ers were excised, weighed, and examined for macro-
scopic lesions. According to standard methods, livers 
were fixed in 10% neutral buffered formalin (Fisher 
Scientific, Pittsburgh, PA) or Z-FIX (ANATECH LTD, 
Battle Creek, MI), dehydrated, embedded in paraffin, 
sectioned serially at 5 µm, and stained with H&E.  
In vivo HCC imaging  
Radio-Labeling. [125I]-FIAU was kindly provided 
by Dr. Dongfeng Pan of University of Virginia. The 
radio-synthesis  followed  a  published  method  [10]. 
[18F]-FHBG was synthesized on-site according to lit-
erature  method  [9,  15].  D-FMAU  was  first  labeled 
with C-11 [16]. F-18 labeling of D-FMAU was reported 




studies  [18].  The  radio-synthesis  of  F-18  labeled  D- 
and L-FMAU were conducted following the general 
approaches  [14], and  were  modified  slightly  in  this 
study according to the recently published methods for 
synthesizing F-18 labeled D-FMAU [19]. H-3 labeled 
D-  and  L-FMAU  were  purchased  from  Moravek 
(Brea, CA) and used for cell uptake assays.  
BLI. To detect luciferase activity using BLI in the 
carcinogen treated mouse which carry dual reporter 
gene tk/Luc, mice belly were shaved before imaging to 
avoid the light absorption by the fur. D-luciferin was 
injected  i.p.  into  the  adult  mice  at  100g/kg  body 
weight.  6  minutes  after  injection,  the  animals  were 
placed supine and side-by-side (target with carcino-
gen  treatment  and  control  animals)  at  the  plate  of 
Xenogen IVIS 200 cooled-CCD camera system (Palo 
Alto, CA) for two 3 minute imaging sessions. During 
imaging, the mice were anesthetized continuously via 
inhalation  of  the  same  isoflurane  gas.  Using  3  min 
instead of 6 min is because the sensitivity of Xenogen 
IVIS 200 is higher than that of PIXIS 1000 that is used 
mainly for initial screening. The BLI images were then 
pseudo-colored and overlaid on top of a conventional 
photograph of the animals.  
PET imaging with FHBG. Two (2) target/control 
pair was placed prone on the imaging bed of a mi-
croPET  scanner  R4  (Siemens/Concord,  Knoxville, 
TN).  A  similar  gas  anesthesia  system  was  used  to 
keep  the  animal  on  the  scanner  bed.  A  20  minute 
transmission scan was conducted using a sealed point 
source to get the attenuation map. 250 uCi (9.25 MBq) 
of [18F]-FHBG in 200 L of saline solution was injected 
via tail vein into each animal. 40 minutes later, a 30 
minutes  emission  scan  was  conducted  in  list  mode 
acquisition.  After  the  scan,  the  acquired  data  were 
binned into 5 minutes frames and reconstructed with 
attenuation correction using the ASIPRO package on 
the R4 scanner. The last frame of the emission images 
was colored in hot-metal and was superimposed on 
the transmission image. Immediately after euthanasia 
of the animals, the abdominal of the animal was open 
to examine the liver tumor and organs for correlation 
with the imaging results. 
Dynamic  PET  imaging  with  D-  and  L-FMAU. 
For  the  next  batch  of  carcinogen-treated  transgenic 
animals, this pair of tracers were applied to the same 
animals  (n=4)  for  microPET  imaging  in  a  sequence 
two days apart. This time, list-mode scans were ac-
quired starting at tracer injection, and lasted for 135 
min. The acquisition was binned into 5-min frames, 
and reconstructed with attenuation correction using 
the same ASIPRO into a dynamic sequence. Regions 
of interests (ROI) were drawn around the liver cancer 
as well as  on a liver lobe without tumor. The time 
activity curves from these ROIs were generated for D- 
and L-FMAU uptakes on the same animals that were 
scanned two days apart.  
Cell isolation. As a make-up study, three (3) ad-
ditional animals were scanned with each tracer two 
days apart for 10 minutes at 50 minutes post-injection 
of each tracer. Tumors from DEN-treated mouse liv-
ers were harvested after imaging from these report-
er-gene knock-in mice. Minced tissues were digested 
with 1mg/ml type IV collagenase for 45 minutes at 
37°C.  After  washing  with  complete  medium  twice, 
cells  were  filtered,  spun  down,  and  re-suspended. 
Cells were grown in DMEM supplemented with fetal 
bovine  serum,  100  units/mL  penicillin,  0.1  mg/mL 
streptomycin,  and  0.25  μg/mL  amphotericin,  Insu-
lin-Transferrin-Selenium-A  Supplement  (Invitrogen) 
and  non-essential  amino  acids  (Sigma),  plated  on 
six-well  plates  pre-coated  with  30  μg/mL  collagen 
and maintained at 37°C in an atmosphere of air and 
5% CO2 to be used later for cell uptake assay. 
Cellular uptake and efflux of L- and D-FMAU. 
For each FMAU tracer, 1x106 cells were used, which 
were cultured in a T75 culture flask; the assay was 
performed within 24 hours after plating/passaging of 
the cells. Each assay is triplicated. First, cells began 
with  incubation  in  5  mL  of  DMEM  (supplemented 
with  10%  FBS,  Pen/Strep/Glutamine,  Fungizone, 
25mM HEPES) and 10 μCi (370 kBq) of H-3 labeled 
either L- or D-FMAU for 5 minutes at 37 °C (pulse). 
After  incubation,  the  media  was  aspirated  and  the 
cells  washed  three  times  with  5  mL  PBS.  5  mL  of 
DMEM was added and left for the time (efflux) peri-
ods of 0, 15, 30, 60, and 90 minutes. After each desig-
nated efflux period, the media was separated from the 
cells. The cells were then washed twice with 5 mL PBS 
and trypsinized with 1 mL of trypsin and transferred 
to a screw-top microcentrifuge tube, and 0.5 mL of 
ice-cold DMEM was added. The tube was centrifuged 
at 1500g for 5 min at 4 °C. After that, the supernatant 
is aspirated and the cells washed/resuspended in 1 
mL  distilled,  deionized  (DDI)  H2O  and  are  centri-
fuged again at 1500g for 5 min at 4°C. After centrifu-
gation, the supernatant was discarded and pellet of 
cells resuspended in 1.2 mL DDI H2O and ten 0.5 mm 
glass beads added to the screw-top microcentrifuge 
tube for cell lysis via beatbeating. 5/6 (1.0 mL) of the 
resulting supernatant was used to measure the total 
radioactivity  with  the  cells  by  liquid  scintillation 
counting.  1/6  (0.2  mL)  was  used  for  protein  meas-
urement via the Bradford method (Bio-Rad Laborato-
ries, Inc., Hercules, CA). The measured radioactivity 
(via liquid scintillation counting as DPM) at each time 
point for each replicate was normalized to the amount 




the difference in volumes. 
Results 
Initial  evaluations:  The  one-day-old  mouse  lit-
ters were imaged by BLI and shown in Supplementary 
Material: Figure S2. As mentioned in the Supplement, 
about half of them were positive for the reporter al-
lele. In addition, it is quite a challenge to perform i.v. 
injection of radio-tracer into the newborns for scinti-
graphic  imaging.  Three  day  after  birth,  pups  were 
successfully  injected  i.v.  with  a  small  amount  of 
[125I]-FIAU.  Two  days  after  injection  (5  days  after 
birth), the non-binding FIAU was cleared out of the 
general circulation and the planar scintigraphy was 
performed  while  the  young  pups  were  put  under 
much  lower  anesthesia  (<0.5%  of  isoflurane  mixed 
with oxygen) to prevent movement during imaging as 
they grew rapidly, and at the same time to ensure that 
the young animals survived the scanning. However, 
that introduced some inadvertent movement. Despite 
of this movement, which cause some blurring during 
the longer (2 minutes comparing to seconds during 
x-ray) scintigraphic scan, positive mice showed liver 
uptake while negative controls had lower abdominal 
non-specific uptake as shown in Supplementary Mate-
rial: Figure S3. When these mice reached the age of 8 
weeks, CCl4 was injected i.v. into these animals. Fig-
ure 2 showed BLI as well as scintigraphic imaging of 
both reporter positive and negative mice 48 hrs after 
CCl4 treatment (24 hrs post FIAU injection). Thyroid 
uptake  was  imaged  for  both  reporter  positive  and 
negative  mice  indicating  free  radioiodide  from 
de-halogenation of labeled FIAU, which served as an 
internal  control  for  I-125  imaging.  All  these  planar 
images  were  used  for  qualitative  assessment  of  the 
newly created animal model. 
PET  imaging  of  HCC  with  FHBG.Having  con-
firmed that luciferase was detected in the fetal liver 
and injured adult liver, but none of the normal adult 
tissues of Afp-TK-ires-Luc mice, it was logical to in-
vestigate whether the tk-luc fusion protein were in-
deed expressed in HCC induced in these mice at the 
levels that could be detected in live animals by BLI 
and PET imaging, respectively. HCC can be readily 
induced in either C3H inbred mice or C57 BL/6j-C3H 
F1 hybrid mice. After treated with carcinogen DEN, 
HCC developed in these mice in a manner similar to 
that in wild-type C57 BL/6j-C3H F1 hybrid mice (data 
not  shown).  BLI  was  used  to  monitor  the  develop-
ment of HCC, and found liver signals early on. mi-
croPET imaging was first performed on these mice 9 
months after DEN treatment. Figure 3 showed a pair 
of DEN-treated and non-treated mice, in which only 
one very strong spot was detected with both BLI and 
later the corresponding PET with FHBG. [18F]-FHBG 
was used  only once on two pairs  of mice due to  a 
scheduling  issue.  Right  after  PET  imaging,  autopsy 
revealed  that  each  of  these  animals  had  numerous 
tumours.  Interesting,  pathological  analysis  revealed 
that  some  of  these  tumours  were  adenoma  (Figure 
3c),  but  others  were  carcinoma  that  did  not  show 
FHBG uptake.  
 
 
Figure 2. Imaging Afp onset in adult liver after the treatment of CCl4. a) is a representative BLI of the positive mice while b) is the same 
mouse in a) but imaging with [125I]-FIAU after BLI. c) is a representative of negative control under-going the same scintigraphic imaging with 





Figure 3. BLI in a) with D-luciferin for luc expression and microPET in b) with FHBG for tk expression of a positive and negative pair. 
Autopsy after imaging was shown in d). The red arrow pointed to Afp positive nodule, which is confirmed as HCC in c) while other liver 
nodules are confirmed as adenoma, the inserts are a portion magnified from their respected histology slide. The yellow arrow pointed to 
the bladder where tracer clearance accumulated. 
 
 
PET imaging of HCC with D- and L-FMAU. Be-
cause some of the liver nodules were not picked up by 
FHBG. Therefore, dynamic PET scans were performed 
on  the  next  batch  of  carcinogen-treated  transgenic 
animals. The pair of tracers, D- and L-FMAU, were 
applied  to  the  same  animals  for  microPET  imaging 
two days apart. Regions of interests (ROI) were drawn 
around  the  liver  cancer  as  well  as  on  a  liver  lobe 
without tumor. The time activity curves of tracer up-
take were generated from these ROIs centered on liver 
cancer  (with  focal  tracer  uptake)  and  a  liver  back-
ground region shown in Figure 4. Both D-FMAU and 
L-FMAU have seen liver tumor uptake where the tk 
gene is expressed under the Afp promoter. The focal 
uptake  was  depicted  differently  between  D-  and 
L-FMAU for the same liver nodule. L-FMAU showed 
better tumor uptake to liver background ratio along 
the timeline.  
Cell uptake assays. Cells derived from the tumor 
post-imaging were divided and pulsed with H-3 la-
beled  D-  and  L-FMAU  separately  for  5  min  is  to 
mimic in vivo tracer accessibility in circulation. The 
tracer efflux from the cells into the medium at differ-
ent time points is used for correlation with dynamic 
PET imaging data. Figure 5 showed comparable cel-
lular tracer uptake between D- and L-FMAU for most 
time points: 30 min, 60 min and 90 min, especially the 
60 min point when the static scan usually takes place. 
This echoed the time activity curves (blue lines) of the 
two tracers in Figure 4. 
Discussion 
Recent  progresses  in  transgenic  and  gene  tar-
geting  technologies  in  mice  have  demonstrated  the 
great power of the use of reporter-gene-based imag-
ing in studying biological processes. We have created 
a  mouse  model  for  studying  acute  liver  injury  and 
naturally occurring hepatocellular carcinoma (HCC) 
using  a  knock-in  gene  targeting  approach.  In  this 




firefly luciferase (luc) and herpes viral thymidine ki-
nase (tk) and the expression is under the control of an 
endogenous Afp promoter. Therefore, both BLI and 
PET imaging  may be used to monitor the status of 
liver,  depending  on  logistics,  cost  and  specific  cir-
cumstances.  
Our  previous  studies  have  shown  that  the  ex-
pression  profiles  of  tk  and  luc  in  these  mice  were 
identical  to  that  of  endogenous  Afp  gene.  Further-
more, the introduction of the tk-IRES-luc cassette into 
the Afp locus and the expression of these exogenous 
proteins did not result in any significant adverse ef-
fects to these mice. The mouse Afp promoter is active 
during embryonic development in several tissues in-
cluding the fetal liver peaking at birth, but it becomes 
inactive  in  normal  adult  mice.  However,  Afp  is 
re-activated when hepatocytes are damaged or trans-
formed  into  HCC  cells.  Both  BLI  with  virtually  no 
background and microPET with radio-tracer uptake 
could be used to image that re-activation as shown in 
Figures  2  &  3.  Comparing  to  the  commonly  used 
xenograft models, this set of mice provides an excel-
lent small animal model for studying liver injury, liver 
cancer and treatment assessment in vivo by monitor-




Figure 4. Tracer comparison between D- and L-FMAU on the same animal models. Although there is a variation for each tracer applied 
a batch of mice, the general trend holds for each tracer. Both D- and L-FMAU showed lasting uptake in the tumor with L-FMAU showed 





Figure 5. Comparison of D- and L-FMAU uptake in multiple liver foci with comparable uptake in cells derived from the liver nodules. 
Showing on the left are PET images from the same animal after stabilization of tracer uptake (30 min post-injection, T30) while D- and 
L-FMAU applied on this batch of mice behaved very similar to their counterparts in Figure 4. Cell uptake assays on the right using derived 
tumor cells post-imaging showed comparable normalized uptake with both H-3 labeled D- and L-FMAU for most time points. 
 
FIAU was used to image the newborns, and later 
to assess acute liver injury. Tracer kinetics of FIAU 
was well known as it circulates in the mice for 24-48 
hrs  for  clearance  [12].  De-halogenation  of  FIAU  in 
vivo over the time was also known [20], and our ini-
tial study showed intense thyroid uptake in all mice. 
FHBG was used in this study by accident, and it did 
not show uptake in some of the liver nodules. FHBG 
was  initially  developed  specifically  for  imaging  a 
point-mutated sr39tk, not the original tk [13]. It is not 
surprising to see this lack of performance in the ani-
mal  model  expressing  the  tk  gene.  Some  of  these 
nodules  were  adenomas,  but  Afp  was  activated  in 
some of the carcinoma as it is well-known that Afp is 
active in 70% of HCC [6]. Comparison studies were 
performed  for  multiple  tracers  through  dynamic 
scans. For the group of the animals shown in Figure 4, 
both D-FMAU and L-FMAU have seen stable uptake 
in the liver tumors. The cellular tracer uptake assays 
using cells derived from these tumor confirmed that. 
However,  there  is  a  slight  difference  in  sig-
nal-to-background  ratio  as  well  as  tracer  clearance 
(tracer kinetics) between D- and L-FMAU. Variations 
exist among each group of mice, but the general trend 
about  a  tracer’s  signal-to-background  ratio  and 
clearance  holds  as  L-FMAU  showed  higher  tumor 
uptake  vs.  liver  background  as  well  as  a  steady 
washout  for  non-binding  molecules.  Unfortunately, 
attempts to establish cell lines from the liver tissues 
surrounding liver tumors/nodules failed. A compar-
ison  on  cellular  uptake  of  various  tracers  between 
these cells and the tumors cells would have explained 
the  signal-to-liver  contrast  shown  in  FMAU  images 
(red lines in Figure 4). Being a non-natural occurring 
nucleoside analog as comparing to its D-enantiomers 
such  as  FLT,  D-FMAU,  etc.,  L-FMAU  seems  to  be 
advantages  for  liver  and  liver  cancer  imaging  due 
maybe to its resistance to hepatic degradation (in he-
patic parenchyma). Future studies would concentrate 
on using L-FMAU for assessing liver injury, and for 
assessment  of  response  to  therapeutics  applied  on 





We  demonstrated  the  use  of  a  newly  created 
mouse model, in which firefly luciferase and a version 
of herpes viral thymidine kinase were expressed only 
in fetal tissues, injured hepatocytes and in HCC cells. 
More  importantly,  the  expressions  of  these  two  re-
porter markers could be detected in naturally occur-
ring HCC tumor by BLI and by PET. Among the po-
tential  PET  tracers  for  imaging  naturally  occurring 
HCC, L-FMAU seems to be better suited. The model 
can  be  further  used  for  early  identification  of  can-
cer-bearing  animals,  for  monitoring  changes  of  the 
disease  in  response  to  therapeutic  interventions.  In 
addition,  the  combination  of  this  model  with  cur-
rently available tracers offers a potential new means 
for monitoring liver injury. 
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